Home > Inhibitors & Agonists > Membrane Transporter/Ion Channel > Proton Pump
Cat. No. Product name CAS No.
DC11515 Azeloprazole

A novel potent proton pump inhibitor that irreversibly inhibits H+,K+-ATPase activity with IC50 of 0.28 uM.

955095-45-1
DC11546 Azeloprazole sodium

A novel potent, orally active proton pump inhibitor that irreversibly inhibits H+,K+-ATPase activity with IC50 of 0.28 uM.

955095-47-3
DC9869 Bamaquimast

Bamaquimast is an inhibitor of proton pump extracted from patent US2005165041, example 138.

135779-82-7
DC6917 Vonoprazan Featured

For the detailed information of Vonoprazan, the solubility of Vonoprazan in water, the solubility of Vonoprazan in DMSO, the solubility of Vonoprazan in PBS buffer, the animal experiment (test) of Vonoprazan, the cell expriment (test) of Vonoprazan, the in vivo, in vitro and clinical trial test of Vonoprazan, the EC50, IC50,and affinity,of Vonoprazan, For the detailed information of Vonoprazan, the solubility of Vonoprazan in water, the solubility of Vonoprazan in DMSO, the solubility of Vonoprazan in PBS buffer, the animal experiment (test) of Vonoprazan, the cell expriment (test) of Vonoprazan, the in vivo, in vitro and clinical trial test of Vonoprazan, the EC50, IC50,and affinity,of Vonoprazan, Please contact DC Chemicals..

881681-00-1
DC10205 Ilaprazole Featured

Ilaprazole (IY-81149) is a proton pump inhibitor; inhibits H+/K+-ATPase with an IC50 of 6.0 μM.

172152-36-2
DC9876 Pantoprazole

Pantoprazole is a proton pump inhibitor used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease.

102625-70-7
DC9135 Pantoprazole Sodium

Pantoprazole sodium salt(SKF96022; Protonix) is a proton pump inhibitor drug used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease.

138786-67-1
DC10356 PF 03716556

PF 03716556 is a potent, and selective acid pump (H+,K+ ATPase) antagonist, with pIC50 value of 6.009.

928774-43-0
DC7306 TAK-438 Featured

TAK-438 is a novel P-CAB (potassium-competitive acid blocker) that reversibly inhibits H+/K+, ATPase with IC50 of 19 nM (pH 6.5), controls gastric acid secretion.

1260141-27-2
DC28253 Abeprazan hydrochloride

Abeprazan hydrochloride (DWP14012 hydrochloride) is a potassium-competitive acid blocker. Abeprazan hydrochloride inhibits H+, K+- ATPase by reversible potassium-competitive ionic binding with no acid activation required. Abeprazan hydrochloride is developed as a potential alternative to proton pump inhibitor for the treatment of acid-related diseases.

1902954-87-3
DC28387 5-Hydroxylansoprazole

5-Hydroxylansoprazole (AG1908) is an active metabolite of Lansoprazole in plasma. Lansoprazole is metabolized by CYP2C19 forming 5-Hydroxylansoprazole. Lansoprazole is a gastric proton-pump inhibitor and is effective in the treatment of various peptic diseases.

131926-98-2
DC41266 Ilaprazole sodium

Ilaprazole (IY-81149) sodium is an orally active proton pump inhibitor. Ilaprazole sodium irreversibly inhibits H+/K+-ATPase in a dose-dependent manner with an IC50 of 6 μM in rabbit parietal cell preparation. Ilaprazole sodium is used for the research of gastric ulcers. Ilaprazole sodium is also a potent TOPK (T-lymphokine-activated killer cell-originated protein kinase) inhibitor.

172152-50-0
DC43999 Tiludronate disodium hemihydrate

Tiludronate (Tiludronic Acid) disodium hemihydrate, an orally active bisphosphonate, can act an osteoregulator. Tiludronate disodium hemihydrate is used for the research of the metabolic bone disorders. Tiludronate disodium hemihydrate is a potent inhibit

155453-10-4
DC45766 Caloxin 2A1 TFA

Caloxin 2A1 TFA is an extracellular plasma membrane Ca2+-ATPase (PMCA) peptide inhibitor. Caloxin 2A1 TFA does not affect basal Mg2+-ATPase or Na+-K+-ATPase.

DC45768 Caloxin 2A1

Caloxin 2A1 is an extracellular plasma membrane Ca2+-ATPase (PMCA) peptide inhibitor. Caloxin 2A1 does not affect basal Mg2+-ATPase or Na+-K+-ATPase.

350670-85-8
DC46868 Zastaprazan

Zastaprazan is a proton pump inhibitor (WO2018008929). Zastaprazan can be used for the research of gastrointestinal inflammatory diseases or gastric acid-related diseases.

2133852-18-1
DC49710 KM91104

KM91104, a cell-permeable V-ATPase inhibitor, specifically targets the a3-b2 subunits of V-ATPase.

304481-60-5
DC70061 2GBI

2GBI (2-guanidinobenzimidazole) is a guanidine derivative that inhibits voltage-gated proton channel Hv1 by binding to the VSD from its intracellular side..

5418-95-1
DC70500 Hv1 inhibitor HIF

Hv1 inhibitor HIF is a novel inhibitor of the voltage-gated proton channel Hv1 interacts with the Hv1 VSD in the up and down states.HIF rapidly inhibits proton conduction in the up state by blocking the open channel.HIF interacts with a second site that is accessible in the down state and is responsible for key features of HIF-mediated inhibition, such as the slow component of current decay and the slow recovery from inhibition.The voltage-gated proton channel Hv1 plays important roles in numerous biological processes, including pH homeostasis, the immune response, and sperm cell function.Hv1 channel belongs to the large family of proteins containing voltage-sensing domains (VSDs), which also includes Nav, Kv, and Cav channels and voltage-sensitive phosphatases.

2247103-43-9
DC70914 YHV98-4

YHV98-4 is a selective inhibitor of proton-selective ion channel Hv1 with IC50 of 0.7 uM; YHV98-4 displays no inhibitory effects against other channels containing VSDs, including hERG, KCNQ2, BK, and Nav1.7 channel. YHV98-4 did not inhibit transient receptor potential V1 (TRPV1) or A1 (TRPA1) at 20 uM, which also contains VSD-like domain. YHV98-4 restores impaired ROS-mediated inflammatory pathway, restores impaired ROS-SHP-1-PI3K/pAKT-CXCL1 pathway and attenuates morphine-induced hyperalgesia and tolerance.

132858-26-5
Page 1 / Total 1 FirstPrevNextLastGoto